Previous 10 | Next 10 |
home / stock / oryzf / oryzf news
Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trial MADRID, Spain and BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging ...
In combination with gilteritinib Primary objectives: to assess safety, tolerability and RP2D Secondary objectives: to assess efficacy MADRID, Spain and BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage bio...
A highly selective HDAC-6 inhibitor Rescues motor-neuronal deficiencies in a Charcot-Marie-Tooth model To start IND enabling studies MADRID, Spain and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biop...
MADRID, Spain and BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will host a virtual panel di...
Strong clinical progress in both oncology and CNS Cash, cash equivalents and marketable securities totaled $22.7 million as of December 31, 2022 MADRID, Spain and BOSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biophar...
BIO CEO & Investor Conference 2023 IASLC 2023 Targeted Therapies of Lung Cancer Meeting 16th Annual European Life Sciences CEO Forum Cancer Epigenetics Institute Symposium: From Genes to Chromatin to Therapeutics BioCapital Europe 2023 BIO-EUROPE Sp...
Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECs Part of a broad collaboration with The Cancer Epigenetics Institute (CEI) MADRID, Spain and BOSTON, Jan. 18, 2023 (GLOBE NEWSWIR...
6th Sachs Annual Neuroscience Innovation Forum 12th Annual LifeSci Advisors Corporate Access Event 41st Annual J.P. Morgan Healthcare Conference Invest Securities Biomed Forum 2023 MADRID, Spain and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Oryzon Genom...
Oryzon Genomics S.A. press release ( OTCPK:ORYZF ): Q3 GAAP EPS of -$0.01. Cash, cash equivalents and marketable securities totaled $27.1 million as of September 30, 2022. For further details see: Oryzon Genomics S.A. GAAP EPS of -$0.01
Virtual Bio-Europe Spring 2022 Kempen Life Sciences Conference Asebio Investor Day MADRID, Spain and CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company levera...
News, Short Squeeze, Breakout and More Instantly...
Oryzon Genomics S.A. Company Name:
ORYZF Stock Symbol:
OTCMKTS Market:
MADRID and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has received “Deci...
All resolutions were approved Additional resolution to increase capital for up to 100 million euros approved 42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a c...
Selected for oral presentation Conference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop th...